AshleyE Rosko1, Ying Huang2, Desiree Jones2, Carolyn J Presley3, Jordon Jaggers4, ReNea Owens5, Michelle Naughton6, Jessica L Krok-Schoen7. 1. The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States of America; Division of Hematology, The Ohio State University, Columbus, OH, United States of America. Electronic address: ashley.rosko@osumc.edu. 2. Division of Hematology, The Ohio State University, Columbus, OH, United States of America. 3. The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States of America; Division of Medical Oncology, The Ohio State University, Columbus, OH, United States of America. 4. College of Medicine, The Ohio State University, Columbus, OH, United States of America. 5. Rehabilitation Services, The Ohio State University, Columbus, OH, United States of America. 6. The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States of America; Cancer Prevention and Control, The Ohio State University, Columbus, OH, United States of America. 7. The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States of America; Division of Medical Dietetics and Health Sciences, School of Health and Rehabilitation Sciences, College of Medicine, The Ohio State University, Columbus, OH, United States of America.
Abstract
Older adults with Hematologic Malignancy (HM) are vulnerable to functional decline secondary to disease and treatment. Interventions for physical deconditioning, in concert with routine hematology care are limited. The feasibility of accrual, retention, and demand for an exercise intervention among a high-risk HM population was piloted. METHODS: Older adults with HM, on active treatment, with functional impairment were recruited prospectively to participate in a 6-month Otago Exercise Programme (OEP). Measures of motivation, self-efficacy, patient identified barriers to exercise, barriers to clinical trial enrollment, study satisfaction, and serious adverse events were captured. RESULTS: 63 patients were approached, 18 declined trial enrollment, 45 consented, 30 patients enrolled in the exercise program. The main barrier for trial enrollment was transportation/travel concerns (n = 15). Of the 45 consented participants, 8 (12.7%) dropped out due to clinical deterioration, 5 (7.9%) withdrew, and 2 (3.2%) were ineligible prior to exercise-intervention intiation. The median age was 75.5 years (range 62-83) with plasma cell dyscrasia (63%), non-Hodgkin lymphoma (20%) and leukemia (17%). Retention of the physical therapist (PT) led-OEP was 76.6% of patients (n = 23/30), and end-of-study retention was 66.7% (n = 20/30). Of the evaluable patients, 23/29 completed the PE-led OEP yielding a completion rate of 79%. Participants were extremely motivated (72.4%) and strongly intended (89.7%) to engage in regular physical activity. Exercising when tired increased from a median score of 50 at Visit 1 to 70 at Visit 2, but dropped significantly to 45 at Visit 3 (p < 0.001). Participants reported significantly lower self-efficacy to exercise over the next 6 months from Visit 1 to Visit 3 (p = 0.001). CONCLUSIONS: Older patients with HM had higher completion of in-person, PT-led exercise compared to at-home, independent exercise. Older adults were motivated and found the program acceptable, yet the ability to sustain a structured exercise program was challenging due to changes in health status. ClinicalTrials.gov Identifier: NCT02791737.
Older adults with Hematologic Malignancy (HM) are vulnerable to functional decline secondary to disease and treatment. Interventions for physical deconditioning, in concert with routine hematology care are limited. The feasibility of accrual, retention, and demand for an exercise intervention among a high-risk HM population was piloted. METHODS: Older adults with HM, on active treatment, with functional impairment were recruited prospectively to participate in a 6-month Otago Exercise Programme (OEP). Measures of motivation, self-efficacy, patient identified barriers to exercise, barriers to clinical trial enrollment, study satisfaction, and serious adverse events were captured. RESULTS: 63 patients were approached, 18 declined trial enrollment, 45 consented, 30 patients enrolled in the exercise program. The main barrier for trial enrollment was transportation/travel concerns (n = 15). Of the 45 consented participants, 8 (12.7%) dropped out due to clinical deterioration, 5 (7.9%) withdrew, and 2 (3.2%) were ineligible prior to exercise-intervention intiation. The median age was 75.5 years (range 62-83) with plasma cell dyscrasia (63%), non-Hodgkin lymphoma (20%) and leukemia (17%). Retention of the physical therapist (PT) led-OEP was 76.6% of patients (n = 23/30), and end-of-study retention was 66.7% (n = 20/30). Of the evaluable patients, 23/29 completed the PE-led OEP yielding a completion rate of 79%. Participants were extremely motivated (72.4%) and strongly intended (89.7%) to engage in regular physical activity. Exercising when tired increased from a median score of 50 at Visit 1 to 70 at Visit 2, but dropped significantly to 45 at Visit 3 (p < 0.001). Participants reported significantly lower self-efficacy to exercise over the next 6 months from Visit 1 to Visit 3 (p = 0.001). CONCLUSIONS: Older patients with HM had higher completion of in-person, PT-led exercise compared to at-home, independent exercise. Older adults were motivated and found the program acceptable, yet the ability to sustain a structured exercise program was challenging due to changes in health status. ClinicalTrials.gov Identifier: NCT02791737.
Authors: Kerry S Courneya; Clare Stevinson; Margaret L McNeely; Christopher M Sellar; Christine M Friedenreich; Carolyn J Peddle-McIntyre; Neil Chua; Tony Reiman Journal: Psychooncology Date: 2011-07-18 Impact factor: 3.894
Authors: Amaia Calderón-Larrañaga; Davide L Vetrano; Graziano Onder; Luis A Gimeno-Feliu; Carlos Coscollar-Santaliestra; Angelo Carfí; Maria S Pisciotta; Sara Angleman; René J F Melis; Giola Santoni; Francesca Mangialasche; Debora Rizzuto; Anna-Karin Welmer; Roberto Bernabei; Alexandra Prados-Torres; Alessandra Marengoni; Laura Fratiglioni Journal: J Gerontol A Biol Sci Med Sci Date: 2017-10-01 Impact factor: 6.053
Authors: Siyar Abdulrazaq; Jackie Oldham; Dawn A Skelton; Terence O'Neill; Luke Munford; Brenda Gannon; Mark Pilling; Chris Todd; Emma K Stanmore Journal: BMC Health Serv Res Date: 2018-07-20 Impact factor: 2.655
Authors: M Cataldi; V De Luca; G Tramontano; C Del Giudice; I Grimaldi; P Cuccaro; P Speranza; G Iadicicco; V Iadicicco; F Carotenuto; P A Riccio; G Di Spigna; A Renzullo; L Vuolo; L Barrea; S Savastano; A Colao; G Liotta; G Iaccarino; P Abete; P Buono; M Vollenbroek-Hutten; M Illario Journal: Transl Med UniSa Date: 2019-01-06
Authors: Rob McCarney; James Warner; Steve Iliffe; Robbert van Haselen; Mark Griffin; Peter Fisher Journal: BMC Med Res Methodol Date: 2007-07-03 Impact factor: 4.615
Authors: Saskia Persoon; Mai J M ChinAPaw; Laurien M Buffart; Roberto D K Liu; Pierre Wijermans; Harry R Koene; Monique C Minnema; Pieternella J Lugtenburg; Erik W A Marijt; Johannes Brug; Frans Nollet; Marie José Kersten Journal: PLoS One Date: 2017-07-20 Impact factor: 3.240
Authors: Kah Poh Loh; Chandrika Sanapala; Erin Elizabeth Watson; Marielle Jensen-Battaglia; Michelle C Janelsins; Heidi D Klepin; Rebecca Schnall; Eva Culakova; Paula Vertino; Martha Susiarjo; Po-Ju Lin; Jason H Mendler; Jane L Liesveld; Eric J Huselton; Kathryn Taberner; Supriya G Mohile; Karen Mustian Journal: Blood Adv Date: 2022-07-12